

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Aklog Lishan			2. Issuer Name and Ticker or Trading Symbol PAVmed Inc. [PAVM]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chairman and CEO		
(Last) ONE GRAND CENTRAL PLACE, SUITE 4600	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2018					
(Street) NEW YORK, NY 10165			4. If Amendment, Date Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants	\$ 5	04/05/2018		D			50,450	10/28/2016	01/29/2022	Common Stock	50,450	(1)	0	D	
Series Z Warrants	\$ 3	04/05/2018		A		25,225		04/05/2018	04/30/2024	Common Stock	25,225	(1)	25,225	D	
Warrants	\$ 5	04/05/2018		D			5,646,562	10/28/2016	01/29/2022	Common Stock	5,646,562	(1)	0	I	By HCFP/Capital Partners III LLC (2)
Series Z Warrants	\$ 3	04/05/2018		A		2,823,281		04/05/2018	04/30/2024	Common Stock	2,823,281	(1)	2,823,281	I	By HCFP/Capital Partners III LLC (2)
Warrants	\$ 5	04/05/2018		D			2,220,532	10/28/2016	01/29/2022	Common Stock	2,220,532	(1)	0	I	By Pavilion Venture Partners LLC (3)
Series Z Warrants	\$ 3	04/05/2018		A		1,110,266		04/05/2018	04/30/2024	Common Stock	1,110,266	(1)	1,110,266	I	By Pavilion Venture Partners LLC (3)
Warrants	\$ 5	04/05/2018		D			20,000	10/28/2016	01/29/2022	Common Stock	20,000	(1)	0	I	By HCFP/AG LLC (4)
Series Z Warrants	\$ 3	04/05/2018		A		10,000		04/05/2018	04/30/2024	Common Stock	10,000	(1)	10,000	I	By HCFP/AG LLC (4)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Aklog Lishan ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165	X	X	Chairman and CEO	
HCFP/Capital Partners III LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X		

Pavilion Venture Partners LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X		
--	--	---	--	--

Signatures

/s/ Dr. Lishan Aklog		04/09/2018
<small>Signature of Reporting Person</small>		<small>Date</small>
/s/ Dr. Lishan Aklog, as manager of HCFP/Capital Partners III LLC		04/09/2018
<small>Signature of Reporting Person</small>		<small>Date</small>
/s/ Dr. Lishan Aklog, as manager of Pavilion Venture Partners LLC		04/09/2018
<small>Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reporting person disposed of the Warrants in exchange for Series Z Warrants in an issuer exchange offer.

(2) Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.

(3) Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.

(4) Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.